Voyager Therapeutics (NASDAQ: VYGR) and Medpace Holdings (NASDAQ:MEDP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.


This table compares Voyager Therapeutics and Medpace Holdings’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Voyager Therapeutics -712.22% -46.15% -32.66%
Medpace Holdings 5.37% 9.32% 5.88%

Insider & Institutional Ownership

40.7% of Voyager Therapeutics shares are held by institutional investors. Comparatively, 16.0% of Medpace Holdings shares are held by institutional investors. 6.0% of Voyager Therapeutics shares are held by company insiders. Comparatively, 25.8% of Medpace Holdings shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Voyager Therapeutics and Medpace Holdings’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Voyager Therapeutics $8.31 million 29.61 -$59.32 million ($2.30) -3.98
Medpace Holdings $378.52 million 3.33 $110.08 million $0.56 57.05

Medpace Holdings has higher revenue and earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Medpace Holdings, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Voyager Therapeutics and Medpace Holdings, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Voyager Therapeutics 0 1 7 0 2.88
Medpace Holdings 0 3 3 0 2.50

Voyager Therapeutics presently has a consensus target price of $24.83, suggesting a potential upside of 171.55%. Medpace Holdings has a consensus target price of $34.00, suggesting a potential upside of 6.42%. Given Voyager Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Voyager Therapeutics is more favorable than Medpace Holdings.


Medpace Holdings beats Voyager Therapeutics on 7 of the 12 factors compared between the two stocks.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain. The Company’s clinical candidate, VY-AADC01, is an adeno-associated virus (AAV) gene therapy product candidate, for the treatment of advanced Parkinson’s disease. VY-AADC01 consists of the AAV2 capsid, which has been used in multiple AAV gene therapy clinical trials for various diseases, and the cytomegalovirus promoter that drives expression of the aromatic L-amino acid decarboxylase (AADC) transgene. Its pipeline also includes VY-SOD101, VY-FXN01, VY-HTT01, VY-TAU01 and VY-NAV01.

Medpace Holdings Company Profile

Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.